IPSEN (OTCMKTS:IPSEY) Short Interest Down 92.8% in May

IPSEN (OTCMKTS:IPSEY) was the target of a significant decrease in short interest during the month of May. As of May 29th, there was short interest totaling 37 shares, a decrease of 92.8% from the May 14th total of 514 shares. Approximately 0.0% of the company’s shares are short sold. Based on an average trading volume of 2,616 shares, the days-to-cover ratio is presently 0.0 days.

IPSEN Price Performance

Shares of IPSEY stock remained flat at $46.75 on Thursday. 49 shares of the stock were exchanged, compared to its average volume of 748. The firm has a 50 day simple moving average of $48.00 and a 200-day simple moving average of $42.92. IPSEN has a one year low of $28.66 and a one year high of $51.10.

Wall Street Analysts Forecast Growth

A number of equities analysts have recently issued reports on the stock. Zacks Research raised shares of IPSEN to a “hold” rating in a research report on Friday, May 29th. HC Wainwright assumed coverage on shares of IPSEN in a research report on Friday, June 5th. They set a “buy” rating on the stock. Finally, Deutsche Bank Aktiengesellschaft reissued a “buy” rating on shares of IPSEN in a research report on Thursday, May 14th. Two equities research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Hold”.

IPSEN Company Profile

Ipsen is a global biopharmaceutical company headquartered in Boulogne-Billancourt, France. Founded in 1929, the company focuses on specialty care areas including oncology, neuroscience and rare diseases. Ipsen develops, manufactures and commercializes innovative medicines that address critical unmet medical needs, offering a diverse portfolio of therapies for both adult and pediatric patient populations.

The company’s oncology franchise includes treatments for prostate, renal and hepatocellular carcinomas, with key products such as Cabometyx (cabozantinib) and Decapeptyl (triptorelin).